Get the Weekly Intelligence Brief — top committee picks every Sunday.
HLN · NYSE · STOCK

Haleon plc

Healthcare Updated August 11, 2026
$9.94
52W $8.65 – $11.28
48/100
$43.73B
19.7
0.24
AI Committee Verdict
Watch
48/100
Conviction: Contested · 50% agreement · 6 analysts
Contested

Is HLN Bullish or Bearish?

Mixed. Innellis AI committee rates Haleon plc (HLN) Watch with a composite score of 48/100 , based on 6 analysts with 50% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +12.43 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -7.57 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -1.8% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Revenue declining -1.8% YoY -- this is not a growth story right now — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Current ratio of 0.92 is tight -- limited short-term liquidity cushion — Risk
  • News sentiment is negative (-0.17 across 6 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
48/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 99%
of 192 Healthcare peers
Value Analyst neutral
58 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
Growth Analyst bearish
15 / 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -1.8% YoY -- this is not a growth story right now
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.92 is tight -- limited short-term liquidity cushion
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
52 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.17 across 6 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
49.8
Neutral
MACD Histogram
-0.029
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$9.30
Resistance
$9.95
Bollinger %B
0.46
Inside Bands
Price vs Moving Averages
EMA 9
$9.96 Below
EMA 21
$9.89 Above
EMA 50
$9.71 Above
EMA 200
$9.73 Above

Fundamental Analysis

Valuation
90
Profitability
69
Financial Health
55
Cash Flow
70
Valuation
P/E Ratio 19.7×
P/B Ratio 1.99×
PEG Ratio 1.05
Dividend Yield 1.94%
52W High $11.28
52W Low $8.65
Quality & Growth
ROE 994.4%
ROA 500.6%
Gross Margin 6476.9%
Operating Margin 2186.8%
Revenue Growth YoY
Debt / Equity 0.52
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 19.7 (inexpensive relative to a 15-40x range); Price-to-book of 2.0x; PEG ratio of 1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 9.9%; Return on assets of 5.0%; Net margin of 15.1%; Gross margin of 64.8%; Current ratio of 0.92 (tight short-term liquidity); Debt-to-equity of 0.52; Free cash flow per share is positive (0.26); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full HLN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore HLN Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime